Saturday, August 13, 2016 5:29:19 PM
Clearly they have inside info relating to their joint products with MNTA, included, but not limited to patent office expectations, Glatopa acceptance and sales, 40 mg likelihood of FDA approval. To sell now suggests a bit of urgency. While the optimists are hoping for good news later this month, which if it were to occur would suggest a slight bump at least in the stock price, selling now appears to make no sense. I can understand the registration to sell so NVS could take advantage of a major pop, but selling shares already suggests that is not their intent or expectation. They certainly are in no need for cash as $55 million has to be chump change for them.
Trying to figure out why now. Could NVS be planning to spin off Sandoz and wants to clean its books of any Sandoz partner holdings prior to a spinoff? Just wildly speculating.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM